<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03313050</url>
  </required_header>
  <id_info>
    <org_study_id>C3571001</org_study_id>
    <nct_id>NCT03313050</nct_id>
  </id_info>
  <brief_title>A Trial To Evaluate A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50-85 Years Of Age</brief_title>
  <official_title>A Phase 1/2, Randomized, Observer-blinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults 50 Through 85 Years Of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 2-stage, phase 1/2, randomized, active-controlled, observer-blinded study with a
      2-arm parallel design in each stage.

      In Stage 1 healthy adults 50 to 64 years of age with no history of pneumococcal vaccination
      will be randomized equally to receive either a single intramuscular dose of multivalent
      pneumococcal conjugate vaccine or a licensed tetanus, diphtheria, acellular pertussis
      combination vaccine (Tdap) (control group).

      In Stage 2 healthy adults 65 to 85 years of age previously vaccinated with Prevnar 13 &gt;=2
      months prior to investigational product administration will be randomized equally to receive
      either a single intramuscular dose of multivalent pneumococcal conjugate vaccine or the
      licensed 23-valent pneumococcal polysaccharide vaccine (control group).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 12, 2017</start_date>
  <completion_date type="Anticipated">May 28, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Observer-blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects reporting prompted local reactions within 14 days after vaccination (redness, swelling, and pain at injection site) in each age group</measure>
    <time_frame>14 days after vaccination</time_frame>
    <description>Describe prompted local reactions after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting prompted systemic events within 14 days after vaccination (fever, headache, fatigue, muscle pain, and joint pain) in each age group</measure>
    <time_frame>14 days after vaccination</time_frame>
    <description>Describe prompted systemic events after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting adverse events within 1 month after vaccination in each age group</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Describe adverse events after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting serious adverse events and newly diagnosed chronic medical conditions within 6 months (both Stage 1 and Stage 2)</measure>
    <time_frame>6 months after vaccination</time_frame>
    <description>Describe SAEs and NDCMCs after vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects reporting serious adverse events and newly diagnosed chronic medical conditions within 12months (Stage 2 only)</measure>
    <time_frame>12 months after vaccination</time_frame>
    <description>Describe SAEs and NDCMCs after vaccination.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal serotype-specific opsonophagocytic activity (OPA) geometric mean titers (GMTs) at 1 month after vaccination</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Describe pneumococcal serotype-specific OPA GMTs after vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pneumococcal serotype-specific OPA geometric mean fold rises (GMFRs) from before vaccination to 1 month after vaccination</measure>
    <time_frame>1 month after vaccination</time_frame>
    <description>Describe pneumococcal serotype-specific OPA GMFRs after vaccination.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">506</enrollment>
  <condition>Pneumococcal Infections</condition>
  <arm_group>
    <arm_group_label>Stage 1 multivalent (ages 50-64 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multivalent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 1 Tdap (ages 50-64 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tdap</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 multivalent (ages 65-85 years)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>multivalent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stage 2 polysaccharide (ages 65-85 years)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>polysaccharide</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Multivalent</intervention_name>
    <description>Pneumococcal conjugate vaccine</description>
    <arm_group_label>Stage 1 multivalent (ages 50-64 years)</arm_group_label>
    <arm_group_label>Stage 2 multivalent (ages 65-85 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tdap</intervention_name>
    <description>Tetanus, diphtheria, acellular pertussis vaccine</description>
    <arm_group_label>Stage 1 Tdap (ages 50-64 years)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>polysaccharide</intervention_name>
    <description>23-valent pneumococcal polysaccharide vaccine</description>
    <arm_group_label>Stage 2 polysaccharide (ages 65-85 years)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage 1: Healthy male or female adults 50 to 64 years of age with no history of
             pneumococcal vaccination

          -  Stage 2: Healthy male or female adults 65 to 85 years of age previously vaccinated
             with Prevnar 13 &gt;= 2 months prior to investigational product administration

        Exclusion Criteria:

          -  Stage 1: Vaccination within 12 months before investigational product administration
             with diphtheria-, pertussis-, or tetanus-containing vaccine

          -  Stage 2: Previous vaccination with any pneumococcal vaccine other than a single prior
             dose of Prevnar 13
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Achieve Clinical Research LLC</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Core Healthcare Group</name>
      <address>
        <city>Cerritos</city>
        <state>California</state>
        <zip>90703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Augusta Family Practice</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Augusta</city>
        <state>Kansas</state>
        <zip>67010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <zip>67114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kentucky Pediatric/Adult Research</name>
      <address>
        <city>Bardstown</city>
        <state>Kentucky</state>
        <zip>40004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Charlotte, LLC</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>PMG Research of Wilmington, LLC</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Omega Medical Research</name>
      <address>
        <city>Warwick</city>
        <state>Rhode Island</state>
        <zip>02886</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Research South, LLC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research Incorporated, Foothill Family Clinic</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>J. Lewis Research, Incorporated/Foothill Family Clinic South</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <zip>84088</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=C3571001&amp;StudyName=A+Phase+1%2F2%2C+Randomized%2C+Observer-blinded+Trial+To+Evaluate+The+Safety%2C+Tolerability%2C+And+Immunogenicity+Of+A+Multivalent+Pneumococcal+Conjugate+Vaccine+In+Healthy+Adults+50+Through+85+Years+Of+Age</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2017</study_first_posted>
  <last_update_submitted>April 30, 2018</last_update_submitted>
  <last_update_submitted_qc>April 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

